UNSPSC 51285204: Trimethoprim hydrochloride

This classification denotes a dihydrofolate reductase inhibitor with the molecular formula C14H18N4O3.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9XE000OU9B. The term trimethoprim hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule trimethoprim hydrochloride under HS 29335995 and SITC 51576. SMILES: COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N.CL.

UNSPSC 51285204 Trimethoprim hydrochloride is a Commodity code representing specific pharmaceutical active pharmaceutical ingredients and finished-form medications procured by state and local health departments and county health systems. Recent state and local solicitations under this code show activity in prescription antibiotic supplies and emergency-response pharmaceuticals, though the tagged opportunities reflect a wider pharmaceutical procurement mix than the code's nominal scope suggests—the Illinois Department of Public Health awarded a piggyback contract for Doxycycline Hyclate and Ciprofloxacin Hydrochloride through the MMCAP Infuse cooperative purchasing vehicle, and Seminole County, Florida sought naloxone and drug deactivation systems. The issuing bodies are state departments of health and county health agencies, procuring through cooperative purchasing consortiums and competitive invitation-for-bid processes to supply public health initiatives, emergency response programs, and community health facilities.

Activity appears concentrated in Florida and Illinois based on recent postings. The Illinois Department of Public Health awarded the MMCAP Infuse piggyback contract to Chartwell Rx LLC on August 28, 2026, for pharmaceutical warehouse supply with a contract value of $2,999,999.11 over three years including renewal periods; Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026, for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries, due July 26, 2023. The code shows sparse recent activity aligned directly to trimethoprim hydrochloride itself; broader pharmaceutical procurement through state health departments and cooperative purchasing vehicles represents the primary opportunity stream under this code.